While many pharmaceutical companies benefit from federal funding for research, this doesn’t necessarily translate to lower prices for patients who ultimately buy the drugs that are developed. In other words, the government is effectively subsidizing companies’ ability to develop drugs and then charge exorbitant prices for them.

Sens. Chris Van Hollen (D-MD) and Rick Scott (R-FL) want to change that.

Read full story.